⌕
Scinai Immunotherapeutics · SCNI · Nasdaq
Tenet 21 · Weak
Compare
$1.55+323.14%At closeTenet 21 · Weak
$1.55+1.19 (+323.14%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Scinai Immunotherapeutics (SCNI) Stock

Scinai Immunotherapeutics (SCNI) closed at $1.55 on Nov 19, 2026; its Tenet Score is 21 of 100 against 486 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Close
$1.55
Nov 19, 2026
Market cap
$10.2Munverified basis
share basis not confirmed
52-week range
0.86 – 14.32
low → high
Tenet Score
21/100
Weak · 486 Healthcare peers

Industry: Drugs · see every company filed here →

Scinai Immunotherapeutics Ltd. scores 21/100. Weak. Quality is the soft spot versus 486 Healthcare peers. Insufficient inputs: Tenet 21 is built from 2 of 4 pillars, from 45% of its inputs. The pillars showing a dash had no data, and Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=486
21/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
9
Health
32
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value & Growth omitted — no data yet.
Value—QualityFHealthDGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Withheld: the share basis behind this valuation is not verified.
P/B
—
Withheld: the share basis behind this valuation is not verified.
P/S
—
no P/S on file
ROE
−92%
TTM through Dec 31, 2025
Operating margin
−575.3%
fiscal 2025, before interest and tax
Net margin
—
Not reported in the company's filings for this period.
Current ratio
1.30
Dec 31, 2025 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).

The whole report, at a glance · every card is a live peek, click any to open the section

About Scinai Immunotherapeutics Ltd.

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing…

Composite computed Nov 20, 2026 · peer basis: Healthcare (n=486) · every glimpse links to its full section with sources · not investment advice.

What sector and industry is Scinai Immunotherapeutics in?

Scinai Immunotherapeutics is in the Healthcare sector and the Drugs industry.

What is Scinai Immunotherapeutics' Tenet Score?

Scinai Immunotherapeutics' Tenet Score is 21 out of 100, ranked against 486 Healthcare peers as of Nov 20, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.